Human T-cell leukemia virus-associated malignancy

Amanda R. Panfil, Michael P. Martinez, Lee Ratner, Patrick L. Green

Research output: Contribution to journalReview articlepeer-review

27 Scopus citations

Abstract

Human T-cell leukemia virus type 1 (HTLV-1) is a tumorigenic delta retrovirus and the causative infectious agent of a non-Hodgkin's peripheral T-cell malignancy called adult T-cell leukemia/lymphoma (ATL). ATL develops in approximately 5% of infected individuals after a significant clinical latency period of several decades. Clinical classifications of ATL include smoldering, chronic, lymphoma, and acute subtypes, with varying median survival ranges of a few months to several years. Depending on the ATL subtype and disease symptoms, treatment options include ‘watchful waiting’, chemotherapy, antiviral therapy, allogeneic hematopoietic stem cell transplantation (alloHSCT), and targeted therapies. Herein we review the characteristics and development of ATL, as well as current and future treatment options and perspectives.

Original languageEnglish
Pages (from-to)40-46
Number of pages7
JournalCurrent Opinion in Virology
Volume20
DOIs
StatePublished - Oct 1 2016

Fingerprint

Dive into the research topics of 'Human T-cell leukemia virus-associated malignancy'. Together they form a unique fingerprint.

Cite this